Compare · LLY vs SMMT
LLY vs SMMT
Side-by-side comparison of Eli Lilly and Company (LLY) and Summit Therapeutics Inc. (SMMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and SMMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 93.7x SMMT ($11.88B).
- Over the past year, LLY is up 48.2% and SMMT is down 39.8% - LLY leads by 88.0 points.
- LLY has been more active in the news (8 items in the past 4 weeks vs 1 for SMMT).
- LLY has more recent analyst coverage (25 ratings vs 22 for SMMT).
- Company
- Eli Lilly and Company
- Summit Therapeutics Inc.
- Price
- $1183.95-0.39%
- $15.29+0.26%
- Market cap
- $1.11T
- $11.88B
- 1M return
- +4.20%
- +17.34%
- 1Y return
- +48.19%
- -39.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 22
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
Latest SMMT
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)
- Co-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)
- Summit Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Summit Therapeutics Announces Proposed Public Offering of Common Stock
- SEC Form S-3ASR filed by Summit Therapeutics Inc.
- Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)
- Co-Chief Executive Officer Zanganeh Mahkam bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)
- COO and CFO Soni Manmeet Singh bought $722,250 worth of shares (50,000 units at $14.45), increasing direct ownership by 2% to 3,123,603 units (SEC Form 4)